Status of gene mutation and copy number of EGFR in 290 cases of non-small cell lung carcinoma

Chinese Journal of Pathology

Volumn 37, Issue 10, 2008, Pages 654-659

  Liang, Zhi Yong ^a   Zeng, Xuan ^a   Zhang, Jing ^a   Wu, Sha Fei ^a   Gao, Jie ^a   Liu, Tong Hua ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Carcinoma, non small cell lung; DNA mutational analysis; In situ hybridization, fluorescence; Receptor, epidermal growth

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADENOCARCINOMA; ARTICLE; CONTROLLED STUDY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MUTATION RATE; SQUAMOUS CELL CARCINOMA; ADULT; AGED; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENETIC DISORDER; GENETICS; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROTO ONCOGENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENES, ERBB-1; GENETIC DISEASES, INBORN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 58049200104     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bach PB, Ginsberg RJ. Epidemiology of lung cancer//Ginsberg RJ. American cancer society atlas of clinical oncology: lung cancer. Hamilton: BC Decker, 2002: 1-3.
2. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol, 2001, 19(6): 1734-1742.
3. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004, 22(9): 1589-1597.
4. Cappuzzo F. EGFR FISH versus mutation: different tests, different end-points. Lung Cancer, 2008, 60(2): 160-165.
5. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500.
6. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol, 2005, 23(11): 2493-2501.
7. Cortes-Funes H, Gomez C, Rosell R, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol, 2005, 16(7): 1081-1086.
8. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol, 2005, 23(11): 2513-2520.
9. Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res, 2005, 11(10): 3750-3757.
10. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol, 2005, 23(28): 6829-6837.
11. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res, 2005, 11(3): 1167-1173.
12. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 2005, 97(5): 339-346.
13. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol, 2005, 23(4): 857-865.
14. Mu XL, Li LY, Zhang XT, et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin Cancer Res, 2005, 11(12): 4289-4294.
15. Zhang XT, Li LY, Mu XL, et al. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol, 2005, 16(8): 1334-1342.
16. Endo K, Konishi A, Sasaki H, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer, 2005, 50(3): 375-384.
17. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res, 1989, 17(7): 2503-2516.
18. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst, 2005, 97(9): 643-655.
19. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-small-cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol, 2008, 26(6): 983-994.
20. Chang JW, Liu HP, Hsieh MH, et al. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients. Lung Cancer, 2008, 61(3): 328-339.
21. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol, 2005, 23(31): 8081-8092.
22. Chinese source
23. Chinese source
24. Qin BM, Chen X, Zhu JD, et al. Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Res, 2005, 15(3): 212-217.
25. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res, 2004, 10(24): 8195-8203.
26. Tokumo M, Toyooka S, Ichihara S, et al. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer, 2006, 53(1): 117-121.
27. Sharma SV, Gajowniczek P, Way IP, et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell, 2006, 10(5): 425-435.
28. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J, 2000, 19(13): 3159-3167.
29. Pugh TJ, Bebb G, Barclay L, et al. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. BMC Cancer, 2007, 7: 128.
30. Godin-Heymann N, Bryant I, Rivera MN, et al. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res, 2007, 67(15): 7319-7326.
31. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res, 2007, 13(10): 2890-2896.
32. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A, 2007, 104(52): 20932-20937.